Floatz logo

Irinotecan

Peritoneal Carcinoma

University of UtahSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Peritoneal Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
CanariaBio Inc.
Phase 3BB
Eloxatin
University of Utah
Phase 2B
STAPULDENCEL
SOTIO a.s.
Phase 3B
Dcvac/Ovca
SOTIO a.s.
Phase 3B
Interferon Gamma-1B
InterMune
Phase 3B

View all 27 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →